

Bilaga 8 Exkluderade studier

Insulinpump (CSII)

Systematiska översikter

Första författare, år och ref	Huvudorsak till exklusion
Cummins, 2010 [1]	Review
Leelarathna, 2011 [2]	Review
Realsen, 2012 [3]	Review

Originalstudier

Första författare, år och ref	Huvudorsak till exklusion
Alemzadeh, 2007 [4]	Ej relevant studiedesign (ingen kontrollgrupp)
Alemzadeh, 2005 [5]	För kort studieperiod (3 dagar)
Alemzadeh, 2009 [6]	Ej relevant insulinsort
Allen, 2009 [7]	Sammanfattning av JDRF (Juvenile diabetes research foundation)
Babar, 2009 [8]	Ej relevant intervention (sluta med pump)
Barnard, 2007 [9]	Review
Batajoo, 2012 [10]	Ej relevant studiedesign (ingen kontrollgrupp)
Battelino, 2004 [11]	Ej relevant studiedesign (ingen kontrollgrupp)
Berghaeuser, 2008 [12]	Ej relevant insulinsort
Bittner, 2004 [13]	Ej relevant studiedesign (ingen kontrollgrupp)
Blackett, 1995 [14]	Ej relevant studiedesign (ingen kontrollgrupp)
Boland, 1999 [15]	Ej relevant insulinsort
Campbell, 2009 [16]	Ej relevant studiedesign (ingen kontrollgrupp)
Carlson, 2008 [17]	Ej relevant population (ej diabetes)
Castorino, 2012 [18]	Review
Chen, 2007 [19]	Ej relevant intervention
Chobot, 2007 [20]	Inga separata pumpdata presenterade
Churchill, 2009 [21]	Review
Cogen, 2007 [22]	Ej relevant studiedesign (ingen kontrollgrupp)

Cohen, 2003 [23]	Ej relevant insulinsort
Cohen, 2007 [24]	Hälsoekonomisk studie
Colino, 2010 [25]	För kort studieperiod (6 veckor)
Cypryk, 2008 [26]	Ej relevant intervention
DiMeglio, 2004 [27]	Ej relevant studiedesign (2-dos i kontrollgrupp)
Fox, 2005 [28]	Ej relevant studiedesign (2-3 injektioner/dag)
Gabbe, 2000 [29]	Ej relevant intervention
Garcia-Garcia, 2007 [30]	Endast 8 personer i CSII-gruppen
Gimenez, 2007 [31]	Ej relevant intervention
DIRECNET, 2003 [32]	För kort studietid (6 dagar) på sjukhus
Hanas, 2006 [33]	Ej relevant insulinsort
Hilliard, 2009 [34]	Ej relevant studiedesign (ingen kontrollgrupp)
Jakisch, 2008 [35]	Typ av insulin ej angivet
Jeha, 2005 [36]	Ej relevant studiedesign (ingen kontrollgrupp)
Johannesen, 2008 [37]	Ej relevant insulinsort
Kaufman, 2002 [38]	Ej relevant studiedesign (ingen kontrollgrupp)
Kordonouri, 2011 [39]	Review
Lapolla, 2003 [40]	Ej relevant intervention
Lebenthal, 2012 [41]	Ej relevant population
Lombardo, 2011 [42]	Ej relevant studiedesign (ingen kontrollgrupp)
Luczynski, 2011 [43]	Ej relevant studiedesign (ingen kontrollgrupp) och fel insulin
Makaya, 2012 [44]	Ej relevant studiedesign (ingen kontrollgrupp)
Maniatis, 2001 [45]	Ej relevant studiedesign (ingen kontrollgrupp)
Minkina-Pedras, 2009 [46]	Ej relevant insulinsort
Muller-Godeffroy, 2009 [47]	Ej relevant studiedesign (ingen kontrollgrupp)
Nabhan, 2009 [48]	Ej relevant insulinsort i kontrollgrupp
Nahata, 2006 [49]	Review
Nicolucci, 2008 [50]	Ej relevant population
Nimri, 2006 [51]	Ej relevant studiedesign (ingen kontrollgrupp)
Nuboer, 2008 [52]	Hälsoekonomisk studie
Nuboer, 2006 [53]	Hälsoekonomisk studie
Ooi, 2011 [54]	Ej relevant studiedesign (ingen kontrollgrupp)

Pankowska, 2010 [55]	Ej relevant insulinsort
Pankowska, 2007 [56]	Ej relevant studiedesign (ingen kontrollgrupp)
Paris, 2009 [57]	För kort studieperiod (1-dagsstudie)
Plotnick, 2003 [58]	Ej relevant studiedesign (ingen kontrollgrupp)
Polak, 2007 [59]	Fallstudie
Rabbone, 2009 [60]	Ej relevant studiedesign (ingen kontrollgrupp)
Ramchandani, 2006 [61]	Ej relevant studiedesign (ingen kontrollgrupp)
Rami, 2003 [62]	Ej relevant studiedesign (1–2-dos i kontrollgrupp)
Schiaffini, 2005 [63]	Ej relevant studiedesign (ingen kontrollgrupp)
Schiaffini, 2007 [64]	Ej relevant insulinsort
Shalitin, 2010 [65]	Ej relevant studiedesign (ingen kontrollgrupp)
Shalitin, 2012 [66]	Ej relevant intervention (onset vs non-onset)
Shalitin, 2011 [67]	Review
Shashaj, 2009 [68]	Ej relevant studiedesign (ingen kontrollgrupp)
Shehadeh, 2004 [69]	Ej relevant studiedesign (ingen kontrollgrupp)
Starkman, 2011 [70]	Ej relevant studiedesign (ingen kontrollgrupp)
Steindel, 1995 [71]	Ej relevant studiedesign (ingen kontrollgrupp)
Sulli, 2003 [72]	Ej relevant studiedesign (ingen kontrollgrupp)
Sulli, 2006 [73]	Ej relevant studiedesign (ingen kontrollgrupp)
Sulmont, 2010 [74]	Ej relevant insulinsort
Szypowska, 2009 [75]	Ej relevant studiedesign (ingen kontrollgrupp)
Weintrob, 2003 [76]	Ej relevant insulinsort
Weintrob, 2004 [77]	Ej relevant insulinsort
Weinzimer, 2004 [78]	Ej relevant studiedesign (ingen kontrollgrupp)
Weinzimer, 2006 [79]	Review
Weinzimer, 2008 [80]	Ej relevant insulinsort
Wilkinson, 2010 [81]	Ej relevant studiedesign (ingen kontrollgrupp)
Willi, 2003 [82]	Ej relevant studiedesign (ingen kontrollgrupp)
Williams, 2005 [83]	Editorial
Wood, 2006 [84]	Ej relevant studiedesign (ingen kontrollgrupp)
Ying, 2011 [85]	Hälsoekonomisk studie
Zeng, 2012 [86]	För kort uppföljningstid (endast 2 veckor med CSII)

Sensor-augmented pump (SAP)

Systematiska översikter

Första författare, år och ref	Huvudorsak till exklusion
Golden, 2012 [87]	Ej relevant intervention

Originalstudier

Första författare, år och ref	Huvudorsak till exklusion
Battelino, 2012 [88]	Redovisas endast i SBU:s rapport "Kontinuerlig subkutan glukosmätning vid diabetes"
Bergental, 2011 [89]	Ej relevant studiedesign (ingen kontrollgrupp)
Danne, 2011 [90]	För kort uppföljningstid (6 veckor)
Frontino, 2012 [91]	Ej relevant studiedesign (ingen kontrollgrupp)
Garg, 2012 [92]	Ej relevant intervention och effektmått (värderar stoppfunktion i pumpen) samt för kort studieperiod (1 dagars studie)
Garg, 2006 [93]	Ej relevant intervention (transkutan CGM) samt för kort studieperiod (1 dagars studie)
Hirsch, 2008 [94]	Redovisas endast i SBU:s rapport "Kontinuerlig subkutan glukosmätning vid diabetes"
Hovorka, 2011 [95]	Ej relevant intervention (closed-loop)
Kamble, 2012 [96]	Ej relevant effektmått (jämför tidsåtgången för diabetesvård)
Kordonouri, 2012 [97]	Redovisas endast i SBU:s rapport "Kontinuerlig subkutan glukosmätning vid diabetes"
Kordonouri, 2010 [98]	Redovisas endast i SBU:s rapport "Kontinuerlig subkutan glukosmätning vid diabetes"
Lee, 2007 [99]	Uppgifter om insulinsorter saknas
Petrovski, 2011 [100]	Ej relevant intervention
Radermecker, 2010 [101]	Ej relevant studiedesign (ingen kontrollgrupp, före- efter-studie)
Scaramuzza, 2011 [102]	Ej relevant studiedesign
Schmidt, 2012 [103]	Ej relevant studiedesign (follow-up efter studie, ingen kontrollgrupp)

Warner, 2011 [104]	Endast abstrakt
Yeaw, 2012 [105]	Review
Zucchini, 2011 [106]	För kort studieperiod (3-dagars studie)

Hälsoekonomiska studier (insulinpump och SAP)

Första författare, år och ref	Huvudorsak till exklusion
Campbell, 2009 [107]	Ej relevant, ej hälsoekonomisk studie
Campbell, 2009 [108]	Ej relevant på grund av studiedesign
Cohen, 2007 [24]	Den effekten som studien baseras på överensstämmer inte med effekten i den systematiska översikt som SBU:s resultat bygger på
Colquitt, 2004 [109]	Den effekten som studien baseras på överensstämmer inte med effekten i den systematiska översikt som SBU:s resultat bygger på
Cummins, 2010 [1]	Den effekten som studien baseras på överensstämmer inte med effekten i den systematiska översikt som SBU:s resultat bygger på
Currie, 2007 [110]	Editorial
David, 2012 [111]	Endast abstrakt
De Vries, 2006 [112]	Letter to editor
DeVries, 2009 [112]	Endast abstrakt
Feltbower, 2006 [113]	Analyserar endast interventionskostnaden
Fortaweng, 2012 [114]	Endast abstrakt
Gabbe, 2000 [29]	Ej randomiserad studie
Giardina, 2009 [115]	Endast abstrakt
Goss, 2010 [116]	Ej om hälsoekonomi
Hammond, 2007 [117]	Kommentar
Home, 2006 [118]	Letter to editor
Home, 2006 [119]	Endast abstrakt

Kamble, 2011a [120]	Endast abstrakt
Kamble, 2011b [121]	Endast abstrakt
Kamble, 2012 [96]	Analyserar endast patientkostnader
Liberatore, 2006 [122]	Ej systematisk review
Lynch, 2010 [123]	Fel design
Mikhailova, 2011 [124]	Endast abstrakt
Neeser, 2009 [125]	Endast abstrakt
Ning, 2010 [126]	Endast abstrakt
Norgaars, 2010 [127]	Den effekten som studien baseras på överensstämmer inte med effekten i den systematiska översikt som SBU:s resultat bygger på
Nuboer, 2006 [53]	Den effekten som studien baseras på överensstämmer inte med effekten i den systematiska översikt som SBU:s resultat bygger på
OHTA, 2009 [128]	Ej om hälsoekonomi
Palmer, 2004 [129]	Letter to editor
Palmer, 2004 [129]	Letter-to-editor
Petkova, 2012 [130]	Endast abstrakt
Phillips, 2009 [131]	Endast abstrakt
Quiroz, 2012 [132]	Endast abstrakt
Roze, 2012 [133]	Den effekten som studien baseras på överensstämmer inte med effekten i den systematiska översikt som SBU:s resultat bygger på
Rubin, 2010 [134]	Ej relevant intervention
Sadri, 2010 [135]	Endast abstrakt
Scuffham, 2003 [136]	Den effekten som studien baseras på överensstämmer inte med effekten i den systematiska översikt som SBU:s resultat bygger på
St Charles, 2009a [137]	Den effekten som studien baseras på överensstämmer inte med effekten i den systematiska översikt som SBU:s resultat bygger på

St Charles, 2009b [138]	Den effekten som studien baseras på överensstämmer inte med effekten i den systematiska översikt som SBU:s resultat bygger på
Steindel, 1995 [139]	Ej relevant, retrospektiv studie
Thong, 2009 [140]	Ej relevant, inget om hälsoekonomi
Ulahannan, 2007 [141]	Ej relevant studiedesign

Referenslista

- Cummins E, Royle P, Snaith A, Greene A, Robertson L, McIntyre L, Waugh N. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. *Health Technol Assess* 2010;14:iii-iv, xi-xvi, 1-181.
- Leelarathna L, Guzder R, Muralidhara K, Evans ML. Diabetes: glycaemic control in type 1. *Clin Evid (Online)* 2011;2011:
- Realsen J, Goettle H, Chase HP. Morbidity and Mortality of Diabetic Ketoacidosis With and Without Insulin Pump Care. *Diabetes Technol Ther* 2012;
- Alemzadeh R, Palma-Sisto P, Holzum M, Parton E, Kicher J. Continuous subcutaneous insulin infusion attenuated glycaemic instability in preschool children with type 1 diabetes mellitus. *Diabetes Technol Ther* 2007;9:339-47.
- Alemzadeh R, Palma-Sisto P, Parton EA, Holzum MK. Continuous subcutaneous insulin infusion and multiple dose of insulin regimen display similar patterns of blood glucose excursions in pediatric type 1 diabetes. *Diabetes Technol Ther* 2005;7:587-96.
- Alemzadeh R, Parton EA, Holzum MK. Feasibility of continuous subcutaneous insulin infusion and daily supplemental insulin glargine injection in children with type 1 diabetes. *Diabetes Technol Ther* 2009;11:481-6.
- Allen NA. Continuous glucose monitoring improved glucose control in adults but not in young adults or children with type 1 diabetes. *Evidence Based Nursing* 2009;12:44-44.
- Babar GS, Ali O, Parton EA, Hoffmann RG, Alemzadeh R. Factors associated with adherence to continuous subcutaneous insulin infusion in pediatric diabetes. *Diabetes Technol Ther* 2009;11:131-7.
- Barnard KD, Lloyd CE, Skinner TC. Systematic literature review: quality of life associated with insulin pump use in Type 1 diabetes. *Diabet Med* 2007;24:607-17.
- Batajoo RJ, Messina CR, Wilson TA. Long-term efficacy of insulin pump therapy in children with type 1 diabetes mellitus. *J Clin Res Pediatr Endocrinol* 2012;4:127-31.
- Battelino T, Ursic-Bratina N, Bratanic N, Zerjav-Tansek M, Avbelj M, Krzisnik C. The use of continuous subcutaneous insulin infusion (CSII) as the treatment of choice in children and adolescents with type 1 diabetes. *Pediatr Endocrinol Rev* 2004;1 Suppl 3:537-9.
- Berghaeuser MA, Kapellen T, Heidtmann B, Haberland H, Klinkert C, Holl RW. Continuous subcutaneous insulin infusion in toddlers starting at diagnosis of type 1 diabetes mellitus. A multicenter analysis of 104 patients from 63 centres in Germany and Austria. *Pediatr Diabetes* 2008;9:590-5.
- Bittner C, von Schutz W, Danne T. [Insulin pump treatment in children and adolescents with type 1 diabetes]. *MMW Fortschr Med* 2004;146:35-7.

14. Blackett PR. Insulin pump treatment for recurrent ketoacidosis in adolescence. *Diabetes Care* 1995;18:881-2.
15. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. *Diabetes Care* 1999;22:1779-84.
16. Campbell F, Macdonald A, Gelder C, Reynolds C, Holland P, Felbower RG. Embedding CSII therapy in the routine management of diabetes in children: a clinical audit of this service in Leeds. *Practical Diabetes International* 2009;26:24-28.
17. Carlson MK. Implementation of insulin infusion guidelines in a neonatal intensive care unit. *Am J Health Syst Pharm* 2008;65:1603-5.
18. Castorino K, Paband R, Zisser H, Jovanovic L. Insulin pumps in pregnancy: using technology to achieve normoglycemia in women with diabetes. *Curr Diab Rep* 2012;12:53-9.
19. Chen R, Ben-Haroush A, Weismann-Brenner A, Melamed N, Hod M, Yogev Y. Level of glycemic control and pregnancy outcome in type 1 diabetes: a comparison between multiple daily insulin injections and continuous subcutaneous insulin infusions. *Am J Obstet Gynecol* 2007;197:404 e1-5.
20. Chobot AP, Deja G, Marcinkowski A, Myrda A, Minkina-Pedras M, Jarosz-Chobot P, Otto-Buczowska E. [Treatment of type 1 diabetes mellitus revealed below 7 years of age in the Diabetes Center of Silesia, Poland]. *Pediatr Endocrinol Diabetes Metab* 2007;13:75-8.
21. Churchill JN, Ruppe RL, Smaldone A. Use of continuous insulin infusion pumps in young children with type 1 diabetes: a systematic review. *J Pediatr Health Care* 2009;23:173-9.
22. Cogen FR, Henderson C, Hansen JA, Streisand R. Pediatric quality of life in transitioning to the insulin pump: does prior regimen make a difference? *Clin Pediatr (Phila)* 2007;46:777-9.
23. Cohen D, Weintrob N, Benzaquen H, Galatzer A, Fayman G, Phillip M. Continuous subcutaneous insulin infusion versus multiple daily injections in adolescents with type I diabetes mellitus: a randomized open crossover trial. *J Pediatr Endocrinol Metab* 2003;16:1047-50.
24. Cohen N, Minshall ME, Sharon-Nash L, Zakrzewska K, Valentine WJ, Palmer AJ. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia. *Pharmacoeconomics* 2007;25:881-97.
25. Colino E, Alvarez MA, Carcavilla A, Alonso M, Ros P, Barrio R. Insulin dose adjustment when changing from multiple daily injections to continuous subcutaneous insulin infusion in the pediatric age group. *Acta Diabetol* 2010;47:1-6.
26. Cypryk K, Kosinski M, Kaminska P, Kozdraj T, Lewinski A. Diabetes control and pregnancy outcomes in women with type 1 diabetes treated during pregnancy with continuous subcutaneous insulin infusion or multiple daily insulin injections. *Pol Arch Med Wewn* 2008;118:339-44.
27. DiMeglio LA, Pottorff TM, Boyd SR, France L, Fineberg N, Eugster EA. A randomized, controlled study of insulin pump therapy in diabetic preschoolers. *J Pediatr* 2004;145:380-4.
28. Fox LA, Buckloh LM, Smith SD, Wysocki T, Mauras N. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. *Diabetes Care* 2005;28:1277-81.

29. Gabbe SG, Holing E, Temple P, Brown ZA. Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus. *Am J Obstet Gynecol* 2000;182:1283-91.
30. Garcia-Garcia E, Galera R, Aguilera P, Cara G, Bonillo A. Long-term use of continuous subcutaneous insulin infusion compared with multiple daily injections of glargine in pediatric patients. *J Pediatr Endocrinol Metab* 2007;20:37-40.
31. Gimenez M, Conget I, Nicolau J, Pericot A, Levy I. Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A case-control study. *Acta Diabetol* 2007;44:34-7.
32. Group. DRiCNDS. The accuracy of the CGMS in children with type 1 diabetes: results of the diabetes research in children network (DirecNet) accuracy study. *Diabetes Technol Ther* 2003;5:781-9.
33. Hanas R, Adolfsson P. Insulin pumps in pediatric routine care improve long-term metabolic control without increasing the risk of hypoglycemia. *Pediatr Diabetes* 2006;7:25-31.
34. Hilliard ME, Goeke-Morey M, Cogen FR, Henderson C, Streisand R. Predictors of diabetes-related quality of life after transitioning to the insulin pump. *J Pediatr Psychol* 2009;34:137-46.
35. Jakisch BI, Wagner VM, Heidtmann B, Lepler R, Holterhus PM, Kapellen TM, et al. Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years. *Diabet Med* 2008;25:80-5.
36. Jeha GS, Karaviti LP, Anderson B, Smith EO, Donaldson S, McGirk TS, Haymond MW. Insulin pump therapy in preschool children with type 1 diabetes mellitus improves glycemic control and decreases glucose excursions and the risk of hypoglycemia. *Diabetes Technol Ther* 2005;7:876-84.
37. Johannesen J, Eising S, Kohlwes S, Riis S, Beck M, Carstensen B, et al. Treatment of Danish adolescent diabetic patients with CSII - a matched study to MDI. *Pediatr Diabetes* 2008;9:23-8.
38. Kaufman FR, Austin J, Neinstein A, Jeng L, Halvorson M, Devoe DJ, Pitukcheewanont P. Nocturnal hypoglycemia detected with the Continuous Glucose Monitoring System in pediatric patients with type 1 diabetes. *Journal of Pediatrics* 2002;141:625-30.
39. Kordonouri O, Hartmann R, Danne T. Treatment of type 1 diabetes in children and adolescents using modern insulin pumps. *Diabetes Res Clin Pract* 2011;93 Suppl 1:S118-24.
40. Lapolla A, Dalfrà MG, Masin M, Bruttomesso D, Piva I, Crepaldi C, et al. Analysis of outcome of pregnancy in type 1 diabetics treated with insulin pump or conventional insulin therapy. *Acta Diabetol* 2003;40:143-9.
41. Lebenthal Y, Lazar L, Benzaquen H, Shalitin S, Phillip M. Patient perceptions of using the OmniPod system compared with conventional insulin pumps in young adults with type 1 diabetes. *Diabetes Technol Ther* 2012;14:411-7.
42. Lombardo F, Scaramuzza AE, Iafusco D. Failure of glycated hemoglobin drop after continuous subcutaneous insulin infusion initiation may indicate patients who discontinue: a 4-year follow-up study in children and adolescents with type 1 diabetes. *Acta Diabetol* 2011;
43. Luczynski W, Szypowska A, Glowinska-Olszewska B, Bossowski A. Overweight, obesity and features of metabolic syndrome in children with diabetes treated with insulin pump therapy. *Eur J Pediatr* 2011;170:891-8.

44. Makaya T, Chatterjee S, Wright NP. Outcomes in children managed on continuous subcutaneous insulin infusion therapy: can we trust the figures? *Practical Diabetes* 2012;29:190-92.
45. Maniatis AK, Toig SR, Klingensmith GJ, Fay-Itzkowitz E, Chase HP. Life with continuous subcutaneous insulin infusion (CSII) therapy: child and parental perspectives and predictors of metabolic control. *Pediatr Diabetes* 2001;2:51-7.
46. Minkina-Pedras M, Jarosz-Chobot P, Polanska J, Kalina MA, Marcinkowski A, Malecka-Tendera E. Prospective assessment of continuous subcutaneous insulin infusion therapy in young children with type 1 diabetes. *Diabetes Res Clin Pract* 2009;85:153-8.
47. Muller-Godeffroy E, Treichel S, Wagner VM. Investigation of quality of life and family burden issues during insulin pump therapy in children with Type 1 diabetes mellitus--a large-scale multicentre pilot study. *Diabet Med* 2009;26:493-501.
48. Nabhan ZM, Kreher NC, Greene DM, Eugster EA, Kronenberger W, DiMeglio LA. A randomized prospective study of insulin pump vs. insulin injection therapy in very young children with type 1 diabetes: 12-month glycemic, BMI, and neurocognitive outcomes. *Pediatr Diabetes* 2009;10:202-8.
49. Nahata L. Insulin therapy in pediatric patients with type I diabetes: continuous subcutaneous insulin infusion versus multiple daily injections. *Clin Pediatr (Phila)* 2006;45:503-8.
50. Nicolucci A, Maione A, Franciosi M, Amoretti R, Busetto E, Capani F, et al. Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. *Diabet Med* 2008;25:213-20.
51. Nimri R, Weintrob N, Benzaquen H, Ofan R, Fayman G, Phillip M. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. *Pediatrics* 2006;117:2126-31.
52. Nuboer R, Borsboom GJ, Zoethout JA, Koot HM, Bruining J. Effects of insulin pump vs. injection treatment on quality of life and impact of disease in children with type 1 diabetes mellitus in a randomized, prospective comparison. *Pediatr Diabetes* 2008;9:291-6.
53. Nuboer R, Bruining GJ. Cost-effectiveness of continuous subcutaneous insulin infusion (CSII) in children: illusion or delusion? *Pediatr Diabetes* 2006;7 Suppl 4:39-44.
54. Ooi HL, Wu LL. Insulin pump therapy in children and adolescents with Type 1 Diabetes: improvements in glycemic control and patients' satisfaction -- Hospital UKM experience. *Med J Malaysia* 2011;66:308-12.
55. Pankowska E, Nazim J, Szalecki M, Urban M. Equal metabolic control but superior caregiver treatment satisfaction with insulin aspart in preschool children. *Diabetes Technol Ther* 2010;12:413-8.
56. Pankowska E, Szypowska A, Lipka M, Skorka A. Sustained metabolic control and low rates of severe hypoglycaemic episodes in preschool diabetic children treated with continuous subcutaneous insulin infusion. *Acta Paediatr* 2007;96:881-4.
57. Paris CA, Imperatore G, Klingensmith G, Petitti D, Rodriguez B, Anderson AM, et al. Predictors of insulin regimens and impact on outcomes in youth with type 1 diabetes: the SEARCH for Diabetes in Youth study. *J Pediatr* 2009;155:183-9 e1.
58. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. *Diabetes Care* 2003;26:1142-6.

59. Polak M, Cave H. Neonatal diabetes mellitus: a disease linked to multiple mechanisms. *Orphanet J Rare Dis* 2007;2:12.
60. Rabbone I, Scaramuzza A, Bobbio A, Bonfanti R, Iafusco D, Lombardo F, et al. Insulin pump therapy management in very young children with type 1 diabetes using continuous subcutaneous insulin infusion. *Diabetes Technol Ther* 2009;11:707-9.
61. Ramchandani N, Ten S, Anhalt H, Sinha S, Ching J, Finkelstein A, Maclaren NK. Insulin pump therapy from the time of diagnosis of type 1 diabetes. *Diabetes Technol Ther* 2006;8:663-70.
62. Rami B, Nachbaur E, Waldhoer T, Schober E. Continuous subcutaneous insulin infusion in toddlers. *Eur J Pediatr* 2003;162:721-2.
63. Schiaffini R, Ciampalini P, Spera S, Cappa M, Crino A. An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes. *Diabetes Metab Res Rev* 2005;21:347-52.
64. Schiaffini R, Patera PI, Bizzarri C, Ciampalini P, Cappa M. Basal insulin supplementation in Type 1 diabetic children: a long-term comparative observational study between continuous subcutaneous insulin infusion and glargine insulin. *J Endocrinol Invest* 2007;30:572-7.
65. Shalitin S, Gil M, Nimri R, de Vries L, Gavan MY, Phillip M. Predictors of glycaemic control in patients with Type 1 diabetes commencing continuous subcutaneous insulin infusion therapy. *Diabet Med* 2010;27:339-47.
66. Shalitin S, Lahav-Ritte T, Lebenthal Y, Devries L, Phillip M. Does the timing of insulin pump therapy initiation after type 1 diabetes onset have an impact on glycemic control? *Diabetes Technol Ther* 2012;14:389-97.
67. Shalitin S, Peter Chase H. Diabetes technology and treatments in the paediatric age group. *Int J Clin Pract Suppl* 2011;76-82.
68. Shashaj B, Sulli N. Difference in insulin usage patterns with pubertal development in children with type 1 diabetes during transition from multiple daily injections to continuous subcutaneous insulin infusion (CSII) and through the CSII treatment. *Diabetes Technol Ther* 2009;11:767-74.
69. Shehadeh N, Battelino T, Galatzer A, Naveh T, Hadash A, de Vries L, Phillip M. Insulin pump therapy for 1-6 year old children with type 1 diabetes. *Isr Med Assoc J* 2004;6:284-6.
70. Starkman H, Frydman E, Bustami R. Glargine basal-bolus insulin regimen versus insulin pump therapy: comparison of glycemic control. *J Pediatr Endocrinol Metab* 2011;24:369-71.
71. Steindel BS, Roe TR, Costin G, Carlson M, Kaufman FR. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. *Diabetes Res Clin Pract* 1995;27:199-204.
72. Sulli N, Shashaj B. Continuous subcutaneous insulin infusion in children and adolescents with diabetes mellitus: decreased HbA1c with low risk of hypoglycemia. *J Pediatr Endocrinol Metab* 2003;16:393-9.
73. Sulli N, Shashaj B. Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up. *Diabet Med* 2006;23:900-6.
74. Sulmont V, Souchon PF, Gouillard-Darnaud C, Fartura A, Salmon-Musial AS, Lambrecht E, et al. Metabolic control in children with diabetes mellitus who are younger than 6 years at diagnosis: continuous subcutaneous insulin infusion as a first line treatment? *J Pediatr* 2010;157:103-7.
75. Szymowska A, Lipka M, Blazik M, Groele L, Pankowska E. Insulin requirement in preschoolers treated with insulin pumps at the onset of type 1 diabetes mellitus. *Acta Paediatr* 2009;98:527-30.

76. Weintrob N, Benzaquen H, Galatzer A, Shalitin S, Lazar L, Fayman G, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. *Pediatrics* 2003;112:559-64.
77. Weintrob N, Schechter A, Benzaquen H, Shalitin S, Lilos P, Galatzer A, Phillip M. Glycemic patterns detected by continuous subcutaneous glucose sensing in children and adolescents with type 1 diabetes mellitus treated by multiple daily injections vs continuous subcutaneous insulin infusion. *Arch Pediatr Adolesc Med* 2004;158:677-84.
78. Weinzimer SA, Ahern JH, Doyle EA, Vincent MR, Dziura J, Steffen AT, Tamborlane WV. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. *Pediatrics* 2004;114:1601-5.
79. Weinzimer SA, Swan KL, Sikes KA, Ahern JH. Emerging evidence for the use of insulin pump therapy in infants, toddlers, and preschool-aged children with type 1 diabetes. *Pediatr Diabetes* 2006;7 Suppl 4:15-9.
80. Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. *Diabetes Care* 2008;31:210-5.
81. Wilkinson J, McFann K, Chase HP. Factors affecting improved glycaemic control in youth using insulin pumps. *Diabet Med* 2010;27:1174-7.
82. Willi SM, Planton J, Egede L, Schwarz S. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. *J Pediatr* 2003;143:796-801.
83. Williams LB, Storch EA, Lewin AB, Geffken GR, Silverstein JH, DiMeglio LA, et al. Selecting families for successful insulin pump therapy... DiMeglio LA, Pottorff TM, Boyd SR et al. A randomized, controlled study of insulin pump therapy in diabetic preschoolers. *J Pediatr* 2004;145:380-4. *Journal of Pediatrics* 2005;146:713-14.
84. Wood JR, Moreland EC, Volkening LK, Svoren BM, Butler DA, Laffel LM. Durability of insulin pump use in pediatric patients with type 1 diabetes. *Diabetes Care* 2006;29:2355-60.
85. Ying AK, Lairson DR, Giardino AP, Bondy ML, Zaheer I, Haymond MW, Heptulla RA. Predictors of direct costs of diabetes care in pediatric patients with type 1 diabetes. *Pediatr Diabetes* 2011;12:177-82.
86. Zeng L, Lu H, Deng H, Mu P, Li X, Wang M. Noninferiority effects on glycemic control and beta-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment. *Diabetes Technol Ther* 2012;14:35-42.
87. Golden SH, Brown T, Yeh HC, Maruthur N, Ranasinghe P, Berger Z, et al. 2012;
88. Battelino T, Conget I, Olsen B, Schutz-Fuhrmann I, Hommel E, Hoogma R, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. *Diabetologia* 2012;55:3155-62.
89. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. *Diabetes Care* 2011;34:2403-5.
90. Danne T, Kordonouri O, Holder M, Haberland H, Golembowski S, Remus K, et al. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. *Diabetes Technol Ther* 2011;13:1129-34.
91. Frontino G, Bonfanti R, Scaramuzza A, Rabbone I, Meschi F, Rigamonti A, et al. Sensor-augmented pump therapy in very young children with type 1 diabetes: an efficacy and feasibility observational study. *Diabetes Technol Ther* 2012;14:762-4.

92. Garg S, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, et al. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. *Diabetes Technol Ther* 2012;14:205-9.
93. Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. *Diabetes Care* 2006;29:2644-49.
94. Hirsch IB, Abelson J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. *Diabetes Technol Ther* 2008;10:377-83.
95. Hovorka R, Kumareswaran K, Harris J, Allen JM, Elleri D, Xing D, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. *BMJ* 2011;342:d1855.
96. Kamble S, Weinfurt KP, Schulman KA, Reed SD. Patient Time Costs Associated with Sensor-Augmented Insulin Pump Therapy for Type 1 Diabetes: Results from the STAR 3 Randomized Trial. *Med Decis Making* 2012;
97. Kordonouri O, Hartmann R, Pankowska E, Rami B, Kapellen T, Coutant R, et al. Sensor augmented pump therapy from onset of type 1 diabetes: late follow-up results of the Pediatric Onset Study. *Pediatr Diabetes* 2012;13:515-8.
98. Kordonouri O, Pankowska E, Rami B, Kapellen T, Coutant R, Hartmann R, et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. *Diabetologia* 2010;53:2487-95.
99. Lee SW, Sweeney T, Clausen D, Kolbach C, Hassen A, Firek A, et al. Combined insulin pump therapy with real-time continuous glucose monitoring significantly improves glycemic control compared to multiple daily injection therapy in pump naive patients with type 1 diabetes; single center pilot study experience. *J Diabetes Sci Technol* 2007;1:400-4.
100. Petrovski G, Dimitrovski C, Bogoev M, Milenkovic T, Ahmeti I, Bitovska I. Is there a difference in pregnancy and glycemic outcome in patients with type 1 diabetes on insulin pump with constant or intermittent glucose monitoring? A pilot study. *Diabetes Technol Ther* 2011;13:1109-13.
101. Radermecker RP, Saint Remy A, Scheen AJ, Bringer J, Renard E. Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump. *Diabetes Metab* 2010;36:409-13.
102. Scaramuzza AE, Iafusco D, Rabbone I, Bonfanti R, Lombardo F, Schiaffini R, et al. Use of integrated real-time continuous glucose monitoring/insulin pump system in children and adolescents with type 1 diabetes: a 3-year follow-up study. *Diabetes Technol Ther* 2011;13:99-103.
103. Schmidt S, Norgaard K. Sensor-Augmented Pump Therapy at 36 Months. *Diabetes Technol Ther* 2012;
104. Warner D, Speer H, McDaniels A, Less J, Daniels M. Use of Carelink Pro Diabetes Therapy Management Software for Improving Patient Outcomes Using Sensor Augmented Pump (SAP) Therapy. *Journal of Pediatric Nursing* 2011;26:282-82.
105. Yeaw J, Lee WC, Aagren M, Christensen T. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes. *J Manag Care Pharm* 2012;18:21-32.
106. Zucchini S, Scipione M, Balsamo C, Maltoni G, Rollo A, Molinari E, et al. Comparison between sensor-augmented insulin therapy with continuous subcutaneous insulin infusion or multiple daily injections in everyday life: 3-day analysis of glucose patterns and sensor accuracy in children. *Diabetes Technol Ther* 2011;13:1187-93.

107. Campbell F, Macdonald A, Gelder C, Reynolds C, Holland P, Feltbower R. Embedding CSII Therapy in the routine management of diabetes in children: A clinical audit of this service in Leeds. *Diabetic Medicine* 2009;26:29.
108. Campbell F, Macdonald AL, Gelder C, Reynolds C, Holland P, Feltbower RG. Embedding CSII therapy in the routine management of diabetes in children: A clinical audit of this service in Leeds. *Practical Diabetes International* 2009;26:24-28.
109. Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. *Health Technol Assess* 2004;8:iii, 1-171.
110. Currie CJ. Reliably assessing the cost-effectiveness of continuous subcutaneous insulin infusion vs. multiple daily injections in the UK: what are the issues? *Diabet Med* 2007;24:1058-9.
111. David G, Shafiroff J, Saulnier A, Gunnarsson C. Multiple daily injection therapy (MDI) versus durable insulin pump therapy in type II diabetics: A breakeven analysis. *Value in Health* 2012;15:A65.
112. DeVries JH. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK: Response to Roze et al. *Diabet Med* 2006;23:709; author reply 08.
113. Feltbower RG, Campbell FM, Bodansky HJ, Stephenson CR, McKinney PA. Insulin pump therapy in childhood diabetes-cost implications for Primary Care Trusts. *Diabet Med* 2006;23:86-9.
114. Fortwaengler K, Rautenberg T, Caruso A. Short term health-economic outcomes of continuous subcutaneous insulin infusion (CSII) in type 1 diabetes: A cost comparison analysis. *Value in Health* 2012;15:A350.
115. Giardina S, Lynch P, Papo NL. A cost-effectiveness analysis of continuous subcutaneous insulin injection vs. multiple daily injections in type-1 diabetes patients in Italy. *Value in Health* 2009;12:A407.
116. Goss PW. Glycaemic control in patients with type 1 diabetes after provision of public hospital-funded insulin pumps. *Med J Aust* 2010;192:107-8.
117. Hammond P. Assessing the cost benefits of insulin pump therapy. *Practical Diabetes International* 2007;24:232.
118. Home PD. Cost-effectiveness of CSII. *Diabet Med* 2006;23:707; author reply 07-8.
119. Home PD. Cost-effectiveness of CSII [1]. *Diabetic Medicine* 2006;23:707.
120. Kamble S, Weinfurt KP, Perry BM, Schulman KA, Reed SD. Patient time and indirect costs associated with sensor-augmented insulin pump therapy in type 1 diabetes. *Value in Health* 2011;14:A84.
121. Kamble S, Perry BM, Shafiroff J, Schulman KA, Reed SD. The cost-effectiveness of initiating sensor-augmented pump therapy versus multiple daily injections of insulin in adults with type 1 diabetes: Evaluating a technology in evolution. *Value in Health* 2011;14:A82.
122. Liberatore Rdel R, Jr., Damiani D. Insulin pump therapy in type 1 diabetes mellitus. *J Pediatr (Rio J)* 2006;82:249-54.
123. Lynch PM, Riedel AA, Samant N, Fan Y, Peoples T, Levinson J, Lee SW. Resource utilization with insulin pump therapy for type 2 diabetes mellitus. *Am J Manag Care* 2010;16:892-6.
124. Mikhailova E, Kulyashova A, Shevkulenko I. Evaluation of the effectiveness of pump therapy in children of Samara Region. *Diabetes Technology and Therapeutics* 2011;13:250-51.
125. Neeser K, Kocher S, Weber C, Heister F. CSII compared to MDI: A health economic analysis in the german health care setting. *Value in Health* 2009;12:A407.

126. Ning G, Lynch P. Cost-effectiveness of CSII in China. *Value in Health* 2010;13:A527.
127. Norgaard K, Sohlberg A, Goodall G. [Cost-effectiveness of continuous subcutaneous insulin infusion therapy for type 1 diabetes]. *Ugeskr Laeger* 2010;172:2020-5.
128. Health Quality O. Continuous Subcutaneous Insulin Infusion (CSII) Pumps for Type 1 and Type 2 Adult Diabetic Populations: An Evidence-Based Analysis. *Ont Health Technol Assess Ser* 2009;9:1-58.
129. Palmer AJ, Roze S, Valentine WJ, Spinass G, Scuffham PA, Carr L. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes: Response to Schuffman and Carr [1] (multiple letters). *Diabetic Medicine* 2004;21:1372-73.
130. Petkova E, Petkova V, Petrova G. Economic evaluation of continuous subcutaneous insulin infusion for children with diabetes-a pilot study. *Value in Health* 2012;15:A352.
131. Phillips G, Evans D, Pritchard L. Continuous subcutaneous insulin infusion for children with type 1 diabetes: An audit of the singleton hospital paediatric. *Pediatric Diabetes* 2009;10:100.
132. Quiroz M, Machado F, Shafiroff J, Gill M, Molina M, Gonzalez P. Insulin pump cost-utility analysis compared to multiple daily injection in type 1 diabetic patients in the Mexican social security institute, 21st century hospital. *Value in Health* 2012;15:A69.
133. Roze S, Valentine WJ, Hanas R, Barsoe C. Projection of health economics benefits of continuous glucose monitoring versus self monitoring of blood glucose in type 1 diabetes, in Sweden. *Value in Health* 2012;15:A69.
134. Rubin RR, Peyrot M, Chen X, Frias JP. Patient-reported outcomes from a 16-week open-label, multicenter study of insulin pump therapy in patients with type 2 diabetes mellitus. *Diabetes Technol Ther* 2010;12:901-6.
135. Sadri H, Bereza BG, Longo CJ. Cost-consequence analysis of CSII vs. MDI: A Canadian perspective. *Value in Health* 2010;13:A290.
136. Scuffham P, Carr L. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes (Structured abstract). In: editor.^editors. *Diabetic Medicine*. ed.; 2003. p 586-93.
137. St Charles ME, Sadri H, Minshall ME, Tunis SL. Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada. *Clin Ther* 2009;31:657-67.
138. St Charles M, Lynch P, Graham C, Minshall ME. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective. *Value Health* 2009;12:674-86.
139. Steindel BS, Roe TR, Costin G, Carlson M, Kaufman FR. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. *Diabetes Research and Clinical Practice* 1995;27:199-204.
140. Thong KY, Fegan PG, Yeap BB. Glycaemic control in patients with type 1 diabetes after provision of public hospital-funded insulin pumps. *Med J Aust* 2009;191:291.
141. Ulahannan T, Myint NN, Lonnen KF. Making the case for insulin pump therapy. *Practical Diabetes International* 2007;24:252-56.